Drug Trial Radar · NCT02031432
CORAL XT - Open-label Extension Trial of the CORAL Trial
Last checked: Nov 20, 2026Latest source record: Jul 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
76
Actual
Start
Dec 18, 2013
Primary completion
Apr 2016
Study completion May 3, 2016
Sponsor
- Lead sponsor
- Tris Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 9, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial was to find out how well cebranopadol is tolerated and how often, and which, adverse reactions occur when it is taken every day for a longer period of time. In addition, information was collected how cebranopadol affects pain and well-being in patients suffering from cancer-related pain.
Conditions
- Pain
- Neoplasms
- Chronic Pain
Interventions
CebranopadolDrug
Film-coated tablet; strengths: 200, 400, or 600 µg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Event (TEAEs)Time frame: Up to 28 weeks (26 weeks of cebranopadol treatment and 2 weeks follow up after the last dose)
Locations
22 sites in 10 countries. Site status is shown where the registry gives one.
AT004
Vienna, Austria
BE001
Sint-Niklaas, Belgium
BG001
Shumen, Bulgaria
BG008
Sofia, Bulgaria
BG003
Sofia, Bulgaria
BG004
Sofia, Bulgaria
DK006
Aalborg, Denmark
DK004
Herlev, Denmark
DE008
Böhlen, Germany
DE010
Munich, Germany
HU011
Nyíregyháza, Hungary
PL012
Będzin, Poland
PL014
Dąbrowa Górnicza, Poland
PL003
Gdansk, Poland
PL010
Gliwice, Poland
RO002
Cluj-Napoca, Romania
RS003
Belgrade, Serbia
RS002
Kamenitz, Serbia
RS005
Zrenjanin, Serbia
SK004
Bratislava, Slovakia
SK001
Prešov, Slovakia
SK005
Pruské, Slovakia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.